肺癌治疗现状与展望.pptVIP

* * * * trials served as the stimulus to investigate the safety and utility of preoperative chemoradiotherapy delivered sequentially (12, 13) or concurrently (14) for N2-positve patients * I、II期有生存区别，III期没有生存区别 * * * * * * * Induction MIC - Surgery vs SurgeryDepierre Trial in Locally Advanced NSCLC MIC + Surgery Surgery Entered 179 176 Response Rate 65% N/A Surgery 94% 99% Median DFS 26.7 mos 12.9 mos Median Survival 37 mos 26 mos 1Year Survival 77.1% 73.3% 2Year Survival 59.2% 52.3% 3 Year Survival 51.6% 41.2% 4Year Survival 43.9% 35.3% MIC = Mitomycin/Ifosfamide/Cisplatin Depierre JCO 200